Behav Brain Res 458:114728
Both are GHSR-1a agonists producing equivalent GH stimulation, but Ipamorelin does not significantly elevate cortisol, ACTH, or prolactin side effects documented with GHRP-6
Sermorelin has been clinically available since the 1990s and has the longer track record
For growth hormone axis research, the CJC-1295/Ipamorelin blend addresses GH pulsatility through two distinct receptor pathways - GHRH receptor stimulation and ghrelin receptor agonism - providing complementary secretagogue coverage within a single preparation
This high-potency dose supports cellular defence against oxidative stress, promotes healthy liver detox pathways, and helps maintain respiratory and immune function.*
Additionally, continuous progress in biotechnological innovation and clinical evidence generation strengthens market confidence and expands the therapeutic applications for glutathione across multiple consumer segments